CoChat

Podocytes maintain high basal levels of autophagy independent of mtor signaling

Open access

The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.

Abstract

While constant basal levels of macroautophagy/autophagy are a prerequisite to preserve long-lived podocytes at the filtration barrier, MTOR regulates at the same time podocyte size and compensatory hypertrophy. Since MTOR is known to generally suppress autophagy, the apparently independent regulation of these two key pathways of glomerular maintenance remained puzzling. We now report that long-term genetic manipulation of MTOR activity does in fact not influence high basal levels of autophagy in podocytes either in vitro or in vivo. Instead we present data showing that autophagy in podocytes is mainly controlled by AMP-activated protein kinase (AMPK) and ULK1 (unc-51 like kinase 1). Pharmacological inhibition of MTOR further shows that the uncoupling of MTOR activity and autophagy is time dependent. Together, our data reveal a novel and unexpected cell-specific mechanism, which permits concurrent MTOR activity as well as high basal autophagy rates in podocytes. Thus, these data indicate manipulation of the AMPK-ULK1 axis rather than inhibition of MTOR as a promising therapeutic intervention to enhance autophagy and preserve podocyte homeostasis in glomerular diseases.Abbreviations: AICAR: 5-aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; ATG: autophagy related; BW: body weight; Cq: chloroquine; ER: endoplasmic reticulum; ESRD: end stage renal disease; FACS: fluorescence activated cell sorting; GFP: green fluorescent protein; i.p.: intra peritoneal; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NPHS1: nephrosis 1, nephrin; NPHS2: nephrosis 2, podocin; PLA: proximity-ligation assay; PRKAA: 5ʹ-AMP-activated protein kinase catalytic subunit alpha; RPTOR/RAPTOR: regulatory associated protein of MTOR, complex 1; RFP: red fluorescent protein; TSC1: tuberous sclerosis 1; ULK1: unc-51 like kinase 1

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/15548627.2019.1705007

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Podocytes exhibit high levels of basal autophagy and autophagic flux. (A) Representative images obtained from cryosections of 4-month old Gfp-Lc3 mice stained for the basement membrane marker NID1/nidogen-1/entactin (red) and GFP-LC3 (green). (B) Two-photon images of glomeruli from Gfp-Lc3 mice perfused with dextran as a marker for glomerular capillaries (in red) displaying autophagosomes in vivo (in green, marked with arrow). (C) Representative images obtained from cryosections of 4-month-old Rfp-Gfp-Lc3 mice stained for NID1 (purple). RFP-LC3 and GFP-LC3 fluorescence is endogenous. (D) Quantification of (C) out of 30 glomeruli from 3 mice each with surrounding tubular cells (** ≤ 0.01, * ≤ 0.05). (E) Cryosections displaying glomeruli (upper panel) and tubular system (lower panel) stained for NID1 (red) and GFP-LC3 (anti-GFP antibody, green) in 4-month-old WT mice with and without chloroquine (4 h after chloroquine [Cq] administration i.p. 100 mg Cq/kg BW). (F) Western blot from immortalized human podocyte cell line and proximal tubular cell line (HK2) for MTORC1 downstream targets and LC3 abundance. (G) Densitometry obtained from (F) (** ≤ 0.01)
Figure 1. Podocytes exhibit high levels of basal autophagy and autophagic flux. (A) Representative images obtained from cryosections of 4-month old Gfp-Lc3 mice stained for the basement membrane marker NID1/nidogen-1/entactin (red) and GFP-LC3 (green). (B) Two-photon images of glomeruli from Gfp-Lc3 mice perfused with dextran as a marker for glomerular capillaries (in red) displaying autophagosomes in vivo (in green, marked with arrow). (C) Representative images obtained from cryosections of 4-month-old Rfp-Gfp-Lc3 mice stained for NID1 (purple). RFP-LC3 and GFP-LC3 fluorescence is endogenous. (D) Quantification of (C) out of 30 glomeruli from 3 mice each with surrounding tubular cells (** ≤ 0.01, * ≤ 0.05). (E) Cryosections displaying glomeruli (upper panel) and tubular system (lower panel) stained for NID1 (red) and GFP-LC3 (anti-GFP antibody, green) in 4-month-old WT mice with and without chloroquine (4 h after chloroquine [Cq] administration i.p. 100 mg Cq/kg BW). (F) Western blot from immortalized human podocyte cell line and proximal tubular cell line (HK2) for MTORC1 downstream targets and LC3 abundance. (G) Densitometry obtained from (F) (** ≤ 0.01)CC BY-NC-ND · PubMed Central
Figure 2. Basal autophagy is independent of MTOR activity in podocytes in vivo. (A) Schematic of generating podocyte-specific deletion of Rptor or Tsc1 using Nphs2-Cre mice and Cre-Lox technique. (B) Cryosections from 2-week-old mice bearing podocyte-specific knockout for Rptor and transgenic for Gfp-Lc3 compared to Gfp-Lc3 WT mice (NID1 in red, GFP-LC3 in green). (C) Quantification of GFP-LC3 autophagosomes per glomerular area out of 30 glomeruli each from 3 mice (ns, not significant). (D) Cryosections from 2-week-old mice bearing podocyte-specific knockout for Tsc1 and transgenic for Gfp-Lc3 compared to Gfp-Lc3 WT mice (NID1 in red, GFP-LC3 in green). (E) Quantification of GFP-LC3 autophagosomes per glomerular area out of 30 glomeruli each from 3 mice (ns, not significant). (F) Western blot out of glomerular lysates obtained from 2-week-old mice for MTORC1 downstream targets and LC3 and SQSTM1 abundance. (G) Densitometry for LC3-II, SQSTM1 and p-RPS6 obtained from 3 WT glomerular lysates and 3 glomerular lysates obtained from 2-week-old mice bearing a podocyte-specific deletion of Rptor or Tsc1, respectively (** ≤ 0.01, * ≤ 0.05, ns, not significant)
Figure 2. Basal autophagy is independent of MTOR activity in podocytes in vivo. (A) Schematic of generating podocyte-specific deletion of Rptor or Tsc1 using Nphs2-Cre mice and Cre-Lox technique. (B) Cryosections from 2-week-old mice bearing podocyte-specific knockout for Rptor and transgenic for Gfp-Lc3 compared to Gfp-Lc3 WT mice (NID1 in red, GFP-LC3 in green). (C) Quantification of GFP-LC3 autophagosomes per glomerular area out of 30 glomeruli each from 3 mice (ns, not significant). (D) Cryosections from 2-week-old mice bearing podocyte-specific knockout for Tsc1 and transgenic for Gfp-Lc3 compared to Gfp-Lc3 WT mice (NID1 in red, GFP-LC3 in green). (E) Quantification of GFP-LC3 autophagosomes per glomerular area out of 30 glomeruli each from 3 mice (ns, not significant). (F) Western blot out of glomerular lysates obtained from 2-week-old mice for MTORC1 downstream targets and LC3 and SQSTM1 abundance. (G) Densitometry for LC3-II, SQSTM1 and p-RPS6 obtained from 3 WT glomerular lysates and 3 glomerular lysates obtained from 2-week-old mice bearing a podocyte-specific deletion of Rptor or Tsc1, respectively (** ≤ 0.01, * ≤ 0.05, ns, not significant)CC BY-NC-ND · PubMed Central
Figure 3. Basal autophagy is independent of MTOR activity in podocytes in vitro. (A) Schematic of generating mice with a podocyte-specific knockout for Tsc1 additionally harboring a Tomato-EGFP allele for primary cell isolation. (B) Schematic of generating mice with a podocyte-specific knockout for Rptor additionally harboring a Tomato-EGFP allele for primary cell isolation. (C) Primary podocytes with and without Rptor-deficiency are stained for LC3 in red (green: endogenous fluorescence due to Tomato-EGFP reporter and Nphs2-Cre). (D) Quantification of LC3 signal out of 30 primary podocytes from 3 mice each (ns, not significant). (E) Schematic illustrating proximity-ligation assay (PLA) for SQSTM1 and LC3. (F) Representative image of primary podocytes with and without Rptor and LC3-SQSTM1-PLA signal in red (green: endogenous fluorescence due to Tomato-EGFP reporter and NHPS2-Cre). (G) Quantification of PLA signal from 30 podocytes obtained from 3 mice each (ns, not significant). (H) Primary podocytes with and without Tsc1-deficiency stained for LC3 in red (green: endogenous fluorescence due to Tomato-EGFP reporter and Nphs2-Cre). (I) Quantification of LC3 signal out of 30 primary podocytes from 3 mice each (ns, not significant). (J) Western blot from primary podocytes for abundance of LC3, SQSTM1 and MTORC1 downstream targets. (K) Densitometry from (I) (** ≤ 0.01, ns, not significant)
Figure 3. Basal autophagy is independent of MTOR activity in podocytes in vitro. (A) Schematic of generating mice with a podocyte-specific knockout for Tsc1 additionally harboring a Tomato-EGFP allele for primary cell isolation. (B) Schematic of generating mice with a podocyte-specific knockout for Rptor additionally harboring a Tomato-EGFP allele for primary cell isolation. (C) Primary podocytes with and without Rptor-deficiency are stained for LC3 in red (green: endogenous fluorescence due to Tomato-EGFP reporter and Nphs2-Cre). (D) Quantification of LC3 signal out of 30 primary podocytes from 3 mice each (ns, not significant). (E) Schematic illustrating proximity-ligation assay (PLA) for SQSTM1 and LC3. (F) Representative image of primary podocytes with and without Rptor and LC3-SQSTM1-PLA signal in red (green: endogenous fluorescence due to Tomato-EGFP reporter and NHPS2-Cre). (G) Quantification of PLA signal from 30 podocytes obtained from 3 mice each (ns, not significant). (H) Primary podocytes with and without Tsc1-deficiency stained for LC3 in red (green: endogenous fluorescence due to Tomato-EGFP reporter and Nphs2-Cre). (I) Quantification of LC3 signal out of 30 primary podocytes from 3 mice each (ns, not significant). (J) Western blot from primary podocytes for abundance of LC3, SQSTM1 and MTORC1 downstream targets. (K) Densitometry from (I) (** ≤ 0.01, ns, not significant)CC BY-NC-ND · PubMed Central
Figure 4. AMPK controls autophagy in podocytes. (A) Representative sections from 2-week-old mice bearing podocyte-specific deletion of Rptor or Tsc1 and controls stained for phosphorylated acetyl-CoA carboxylase Ser79 (p-ACACA) in red and NPHS1 (green). (B) Western blot out of glomerular lysates obtained from 2-week-old mice (genotype as indicated) for PRKAA and ULK1 and respective phosphorylation sites. (C) Densitometry for p-PRKAA Thr172 obtained from 3 WT glomerular lysates and 3 glomerular lysates obtained from 2-week-old mice bearing a podocyte-specific deletion of Rptor or Tsc1, respectively (** ≤ 0.01, * ≤ 0.05). (D) Densitometry for p-ULK1 Ser757, p-ULK1 Ser555 and p-ULK1 Ser317 obtained from 3 WT glomerular lysates and 3 glomerular lysates obtained from 2-week-old mice bearing a podocyte-specific deletion of Rptor or Tsc1, respectively (** ≤ 0.01, * ≤ 0.05). (E) Western blot from primary podocytes treated with AICAR (1 mM) for the time indicated (12 h or 24 h) to assess the abundance of p-ULK1 Ser555, p-PRKAA Thr172 and p-RPS6 Ser235/236. (F-H) Densitometry from (E) (** ≤ 0.01, * ≤ 0.05)
Figure 4. AMPK controls autophagy in podocytes. (A) Representative sections from 2-week-old mice bearing podocyte-specific deletion of Rptor or Tsc1 and controls stained for phosphorylated acetyl-CoA carboxylase Ser79 (p-ACACA) in red and NPHS1 (green). (B) Western blot out of glomerular lysates obtained from 2-week-old mice (genotype as indicated) for PRKAA and ULK1 and respective phosphorylation sites. (C) Densitometry for p-PRKAA Thr172 obtained from 3 WT glomerular lysates and 3 glomerular lysates obtained from 2-week-old mice bearing a podocyte-specific deletion of Rptor or Tsc1, respectively (** ≤ 0.01, * ≤ 0.05). (D) Densitometry for p-ULK1 Ser757, p-ULK1 Ser555 and p-ULK1 Ser317 obtained from 3 WT glomerular lysates and 3 glomerular lysates obtained from 2-week-old mice bearing a podocyte-specific deletion of Rptor or Tsc1, respectively (** ≤ 0.01, * ≤ 0.05). (E) Western blot from primary podocytes treated with AICAR (1 mM) for the time indicated (12 h or 24 h) to assess the abundance of p-ULK1 Ser555, p-PRKAA Thr172 and p-RPS6 Ser235/236. (F-H) Densitometry from (E) (** ≤ 0.01, * ≤ 0.05)CC BY-NC-ND · PubMed Central
Figure 5. Activation of AMPK stimulates autophagy independently of MTORC1 activity. (A) Western blot from Tsc1-deficient podocytes and corresponding WT controls with and without AICAR treatment (1 mM, 24 h) to assess the abundance of phosphorylated forms of ULK1 and PRKAA as indicated. (B) Densitometry from (A) (** ≤ 0.01, * ≤ 0.05). (C) Representative section from 2-week-old mice bearing podocyte-specific deletion of Rptor with and without AICAR treatment (500 mg/kg BW 24 h and 4 h before harvest) stained with LC3 (red) and NPHS1/nephrin in green. (D) Representative section from 2-week-old mice bearing podocyte-specific deletion of Rptor with and without AICAR treatment (500 mg/kg BW 24 h and 4 h before harvest) stained with SQSTM1 (red) and NPHS1/nephrin in green. (E) Quantification of LC3 puncta per glomerular area (n = 3 each, 30 glomeruli counted per mouse, * ≤ 0.05). (F) Quantification of SQSTM1 puncta per glomerular area (n = 3 each, 30 glomeruli counted per mouse, * ≤ 0.05). (G) Western blot from glomerular lysates from 2-week-old mice bearing podocyte-specific deletion of Rptor with and without AICAR treatment (500 mg/kg BW 24 h and 4 h before harvest) to assess the abundance of LC3-II. (H) Densitometry from (G) (* ≤ 0.05)
Figure 5. Activation of AMPK stimulates autophagy independently of MTORC1 activity. (A) Western blot from Tsc1-deficient podocytes and corresponding WT controls with and without AICAR treatment (1 mM, 24 h) to assess the abundance of phosphorylated forms of ULK1 and PRKAA as indicated. (B) Densitometry from (A) (** ≤ 0.01, * ≤ 0.05). (C) Representative section from 2-week-old mice bearing podocyte-specific deletion of Rptor with and without AICAR treatment (500 mg/kg BW 24 h and 4 h before harvest) stained with LC3 (red) and NPHS1/nephrin in green. (D) Representative section from 2-week-old mice bearing podocyte-specific deletion of Rptor with and without AICAR treatment (500 mg/kg BW 24 h and 4 h before harvest) stained with SQSTM1 (red) and NPHS1/nephrin in green. (E) Quantification of LC3 puncta per glomerular area (n = 3 each, 30 glomeruli counted per mouse, * ≤ 0.05). (F) Quantification of SQSTM1 puncta per glomerular area (n = 3 each, 30 glomeruli counted per mouse, * ≤ 0.05). (G) Western blot from glomerular lysates from 2-week-old mice bearing podocyte-specific deletion of Rptor with and without AICAR treatment (500 mg/kg BW 24 h and 4 h before harvest) to assess the abundance of LC3-II. (H) Densitometry from (G) (* ≤ 0.05)CC BY-NC-ND · PubMed Central
Figure 6. Effects of acute and long-term pharmacological inhibition of MTORC1 activity on autophagy. (A) Schematic of the short-term treatment regimen (rapamycin vs. vehicle, n = 5 each, rapamycin dose: 10 mg/kg BW i.p. for 3 d). (B) Quantification of GFP-LC3 autophagosomes per glomerular area out of 30 glomeruli each from 5 mice per group (vehicle vs. rapamycin). (C) Representative cryosections from 16-week-old mice transgenic for GFP-LC3 with and without rapamycin treatment (NID1 in red, GFP-LC3 in green, rapamycin dose: 10 mg/kg BW i.p. for 3 d). (D) Representative western blot from glomerular lysates from rapamycin and vehicle treated mice (WT mice, n = 3 each, rapamycin dose: 10 mg/kg BW i.p. for 3 d). (E) Densitometric quantification of (D) (** ≤ 0.01, * ≤ 0.05). (F) Schematic of the long-term treatment regimen (rapamycin dose: 4 mg/kg BW i.p. for 3 weeks). (G) Quantification of serum levels of rapamycin (n = 6 each) (*** ≤ 0.001). (H) Representative western blot from glomerular lysates from rapamycin long-term, short-term and vehicle treated mice. (I) Densitometry from 3 glomerular lysates of each treatment and vehicle controls for LC3-II, SQSTM1 and p-RPS6 Ser235/236 (** ≤ 0.01, ns, not significant). LT, long-term; ST, short-term
Figure 6. Effects of acute and long-term pharmacological inhibition of MTORC1 activity on autophagy. (A) Schematic of the short-term treatment regimen (rapamycin vs. vehicle, n = 5 each, rapamycin dose: 10 mg/kg BW i.p. for 3 d). (B) Quantification of GFP-LC3 autophagosomes per glomerular area out of 30 glomeruli each from 5 mice per group (vehicle vs. rapamycin). (C) Representative cryosections from 16-week-old mice transgenic for GFP-LC3 with and without rapamycin treatment (NID1 in red, GFP-LC3 in green, rapamycin dose: 10 mg/kg BW i.p. for 3 d). (D) Representative western blot from glomerular lysates from rapamycin and vehicle treated mice (WT mice, n = 3 each, rapamycin dose: 10 mg/kg BW i.p. for 3 d). (E) Densitometric quantification of (D) (** ≤ 0.01, * ≤ 0.05). (F) Schematic of the long-term treatment regimen (rapamycin dose: 4 mg/kg BW i.p. for 3 weeks). (G) Quantification of serum levels of rapamycin (n = 6 each) (*** ≤ 0.001). (H) Representative western blot from glomerular lysates from rapamycin long-term, short-term and vehicle treated mice. (I) Densitometry from 3 glomerular lysates of each treatment and vehicle controls for LC3-II, SQSTM1 and p-RPS6 Ser235/236 (** ≤ 0.01, ns, not significant). LT, long-term; ST, short-termCC BY-NC-ND · PubMed Central
Figure 7. Activation of AMPK stimulates autophagy independently of MTOR activity. (A) AMPK activity is reduced if MTORC1 signaling is genetically impaired (activating phosphorylation sites at ULK1 are displayed in green, inhibitory sites are in red). (B) Inhibitory signals on ULK1 by genetically induced MTORC1 hyperactivity are compensated by active AMPK signaling. (C) Pharmacological activation of AMPK is able to induce autophagy in podocytes by activating ULK1. (D) MTORC1 can be bypassed in autophagy regulation as it occurs in the genetic model of MTORC1 inhibition by direct phosphorylation of ULK1 by AMPK. (E) Short-term treatment with rapamycin inhibits MTORC1 activity and activates AMPK leading to increased levels of autophagy. (F) Long-term treatment with rapamycin is compensated by reduced AMPK signaling in regard to autophagy regulation
Figure 7. Activation of AMPK stimulates autophagy independently of MTOR activity. (A) AMPK activity is reduced if MTORC1 signaling is genetically impaired (activating phosphorylation sites at ULK1 are displayed in green, inhibitory sites are in red). (B) Inhibitory signals on ULK1 by genetically induced MTORC1 hyperactivity are compensated by active AMPK signaling. (C) Pharmacological activation of AMPK is able to induce autophagy in podocytes by activating ULK1. (D) MTORC1 can be bypassed in autophagy regulation as it occurs in the genetic model of MTORC1 inhibition by direct phosphorylation of ULK1 by AMPK. (E) Short-term treatment with rapamycin inhibits MTORC1 activity and activates AMPK leading to increased levels of autophagy. (F) Long-term treatment with rapamycin is compensated by reduced AMPK signaling in regard to autophagy regulationCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 100

Metadata

Authors
Bork, T., Liang, W., Yamahara, K., Lee, P., Tian, Z., Liu, S., Schell, C., Thedieck, K., Hartleben, B., Patel, K., Tharaux, P.-L., Lenoir, O., & Huber, T. B.
Affiliations
  • University of Freiburg (DE)
  • Shiga University of Medical Science (JP)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Carl von Ossietzky Universität Oldenburg (DE)
  • Institute of Pathology, Hannover Medical School, Hannover, Germany
  • Inserm (FR)
Corresponding author
Huber, Tobias B.
Venue
Autophagy
Published
2019-12-23
Volume
16
Issue
11
Pages
1932-1948
ISSN
  • 1554-8627 (ISSN-L)
  • 1554-8635
OpenAlex
W2961174880
Cited by
100
References
94
Citations by year
2026: 7 · 2025: 11 · 2024: 12 · 2023: 20 · 2022: 22 · 2021: 14 · 2020: 14
FWCI
9.52
Type
journal article
Language
en
Open access
Locations
  • Autophagy (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • CentAUR (University of Reading) (submittedVersion)
  • HAL (submittedVersion)
  • HAL (submittedVersion, other-oa)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
Funders
  • German Research Foundation Heisenberg Program (HU1016/8-2, HU1016/5-1)
  • H2020-IMI2 BEAt-DKD (115974)
  • BMBF-STOP-FSGS (01GM1518C)
  • German Research Foundation (CRC992, CRC1192, TH 1358/3-1, CRC1140)
  • National Natural Science Foundation of China (81470912)
  • BMBF GlioPATH (01ZX1402B)
  • BMBF MAPTor-NET (031A426B)
  • MESI-STRAT (754688)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
podocytes, basal autophagy, mTOR signaling, AMPK, ULK1, podocyte hypertrophy, glomerular disease, autophagy regulation, nephrosis
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Animals, Autophagy, Humans, Mice, Transgenic, Signal Transduction, Sirolimus, Podocytes, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.